TORONTO, Oct. 1, 2018 /CNW/ - Delivra Corp. (TSXV: DVA -
"Delivra" or the "Company"), a scientific and biotechnology
company, today announced that it has recently received inquiries
from a number of interested parties in relation to the Company's
proprietary transdermal delivery system platform, including its
proprietary applications for the cannabis and pharma
industries.
As a result of these inquiries, the Company has engaged
Canaccord Genuity Corp. to act as exclusive financial advisor to
identify, review, analyze and explore the range of strategic and
other opportunities available to the Company within the cannabis
and pharma industries. There can be no assurance that the Company
will enter into any transaction, that there will be any change in
the operation or ownership of the Company, or that the Company will
take any other corporate action as a result of the review.
Delivra has not set a timetable for completion of the review
process and it does not intend to disclose further
developments with respect to the review unless and until required
by law or until such disclosure is deemed appropriate by the
Company. Delivra cautions that there are no guarantees that the
process will result in a transaction of any kind, and if a
transaction is undertaken, that there is no guarantee as to its
terms or timing.
ABOUT DELIVRA CORP.
Delivra Corp. is a specialty biotechnology company having a
proprietary transdermal delivery system platform that can shuttle
pharmaceutical and natural molecules through the skin, in a
targeted manner. Delivra manufactures and sells a growing line of
natural topical creams with the proprietary transdermal delivery
system platform under the LivReliefTM brand, for
conditions such as joint and muscle pain, nerve pain, varicose
veins, wound healing, and under the LivSportTM brand for
sports performance. LivReliefTM products are available
in pharmacies, grocery chains, and independent health food stores
across Canada, including, but not
limited to, Shoppers Drug Mart, Walmart, Loblaw, Rexall,
Pharmasave, London Drugs, and on-line at www.livrelief.com. In
parallel with its consumer products business, Delivra also has a
mandate to license its patent-pending, proprietary transdermal
delivery technology platform to pharmaceutical companies globally,
for the repurposing of pharmaceutical molecules transdermally to
treat a broad range of conditions, along with licensing its
over-the-counter products globally. Delivra is headquartered in
Hamilton, Ontario and has a
research and development laboratory in Charlottetown, Prince Edward Island.
Further information on Delivra can be found at
www.delivracorp.com and www.livrelief.com.
Cautionary Note Regarding Forward-Looking Statements
This news release includes certain information and statements
about management's view of future events, expectations, plans and
prospects that constitute "forward-looking statements", which are
not comprised of historical facts. Forward-looking statements may
be identified by such terms as "believes", "anticipates",
"intends", "expects", "estimates", "may", "could", "would", "will",
or "plan", and similar expressions. Specifically, forward-looking
statements in this news release include, without limitation,
statements regarding: the Company's anticipated review with respect
to strategic and other opportunities available to the Company and
the transactions (if any) that may result therefrom. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Delivra to differ materially from those
anticipated or implied in such forward-looking statements. The
Company believes that the expectations reflected in these
forward-looking statements are reasonable, but there can be no
assurance that actual results will meet management's expectations.
In formulating the forward-looking statements contained herein,
management has assumed that business and economic conditions
affecting Delivra will continue substantially in the ordinary
course and will be favourable to Delivra; that the Company will
continue to complete orders with existing customers and control
product pricing and expenses that clinical testing results will
justify commercialization of the Company's drug candidates; that
Delivra will be able to obtain all requisite regulatory approvals
to commercialize its drug candidates, that such approvals will be
received on a timely basis, and that Delivra will be able to find
suitable partners for development and commercialization of its
products and intellectual property on favourable terms. Although
these assumptions were considered reasonable by management at the
time of preparation, they may prove to be incorrect. Factors that
may cause actual results to differ materially from those
anticipated by these forward-looking statements include:
uncertainties associated with obtaining regulatory approval to
perform clinical trials and market products; the need to establish
additional corporate collaborations, distribution or licensing
arrangements; the Company's ability to raise additional capital if
and when necessary; changes in equity markets, inflation, changes
with respect to the content or timing of legislation with respect
to the regulation of the sale or use of cannabis; and changes in
exchange rates; and other factors as described in detail in
Delivra's public filings, all of which may be viewed on SEDAR
(www.sedar.com). Given these risks and uncertainties, readers are
cautioned not to place undue reliance on such forward-looking
statements and information, which are qualified in their entirety
by this cautionary statement. Except as required by law, Delivra
disclaims any intention and assumes no obligation to update or
revise any forward-looking statements to reflect actual results,
whether as a result of new information, future events, changes in
assumptions, changes in factors affecting such forward-looking
statements or otherwise.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this
release.
SOURCE Delivra Corp
